Patients Chronic kidney disease: treating a silent killer In November, NICE backed NHS use of AstraZeneca’s diabetes and heart failure drug Forxiga for the treatment of chronic kidney disease.
Views & Analysis AstraZeneca on expanding its diabetes research franchise AstraZeneca is hoping to build a strong focus on cardiovascular, renal, and metabolic (CVRM) diseases.
News Disc maps out US filing for porphyria drug bitopertin Disc Medicine has charted a route to market for bitopertin, its drug candidate for rare disease erythropoietic protoporphyria (EPP), after meeting with the FDA.
Sales & Marketing Sponsored Global reach, personal touch: Mastering customer engagement ... In today's interconnected pharma market, the ability to scale engagement across borders is essential for survival and growth.
